ReviewCurrent cardiology reports2010
What have we learned about plaque rupture in acute coronary syndromes?
Review in Current cardiology reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 47 citations in OpenAlex.
- The impact of anti-inflammatory cytokines provoked by CD163 positive macrophages on ventricular functional recovery after myocardial infarction.Journal of thrombosis and thrombolysis · 2014Trial
- PPARγ in Atherosclerotic Endothelial Dysfunction: Regulatory Compounds and PTMs.International journal of molecular sciences · 2023Review
- Factors Associated with the Extent of Coronary Artery Disease and the Attained Outcome of Percutaneous Coronary Intervention at Gesund Cardiac and Medical Center, Addis Ababa, Ethiopia.Ethiopian journal of health sciences · 2022Observational
- Is There a Link between COVID-19 Infection, Periodontal Disease and Acute Myocardial Infarction?Life (Basel, Switzerland) · 2021Review
- Optical Coherence Tomography of Plaque Vulnerability and Rupture: JACC Focus Seminar Part 1/3.Journal of the American College of Cardiology · 2021Review
- Article
- Effects of Olive Oil Phenolic Compounds on Inflammation in the Prevention and Treatment of Coronary Artery Disease.Nutrients · 2017Review
- Prediction of cardiovascular outcomes by imaging coronary atherosclerosis.Cardiovascular diagnosis and therapy · 2016Review
- Association between three single nucleotide polymorphisms in eotaxin (CCL 11) gene, hexanucleotide repetition upstream, severity and course of coronary atherosclerosis.Journal of applied genetics · 2012Article
- The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients.The Journal of infectious diseases · 2012Review
- The fat-fed apolipoprotein E knockout mouse brachiocephalic artery in the study of atherosclerotic plaque rupture.Journal of biomedicine & biotechnology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common cause of acute coronary syndrome (ACS) is rupture of an atherosclerotic lesion containing a large necrotic core and a thin fibrous cap followed by acute luminal thrombosis because the rupture of the thin fibrous cap allows contact of the platelets with the highly thrombogenic necrotic core. Pathologic studies have suggested that the precursor of the ruptured plaque is the so-called thin cap fibroatheroma (TCFA). Unfortunately, true natural history studies of TCFAs and their transition to ruptured plaques are rare. Most of the data and concepts have been inferred from studies performed at a single point in time. Intravascular ultrasound (IVUS) studies have shown ruptured plaques in approximately two thirds of ACS culprit lesions and occur in predictable locations. The features that differentiate secondary, nonculprit plaque ruptures from those that cause ACS events appear to be superimposed thrombosis and lumen compromise, either from the thrombus or from the underlying lesion. Secondary plaque ruptures appear to heal with optimal medical therapy. In vivo definitions of TCFAs have been derived from pathology study to include positive remodeling, a fibrous cap less than 100 microm (and perhaps <65 microm) at its minimum thickness, macrophage infiltration especially in the thin fibrous cap, a large lipid/necrotic core often containing hemorrhage and/or speckled or diffuse calcification (not enough to increase plaque stability although the absence of any calcium is also rare in rupture-prone plaques), and abundant intraplaque vasa vasorum and/or hemorrhage. Early data from in vivo imaging have substantiated the pathologic observations, but have also suggested that spontaneous stabilization of TCFAs with medical therapy alone is possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.